A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease

The goal of this clinical trial is to learn if study drug Fosamprenavir-Sodium Alginate (FOS-SA) administered orally improves symptoms for Proton Pump Inhibitor (PPI)-refractory Gastro Esophageal Reflux Disease (GERD).
The main questions it aims to answer are:
1. Does FOS-SA significantly improve heartburn severity over the 8-week treatment period
2. Does FOS-SA significantly improve regurgitation frequency over the 8-week treatment period
3. Does FOS-SA significantly improve symptoms of persistent GERD over the 8-week treatment period
Researchers will compare FOS-SA to a placebo (a look-alike substance that contains no active drug) to see if FOS-SA works to treat PPI-refractory GERD.
Participants will:
1. Take FOS-SA or placebo every day BID (twice a day) for 8 weeks
2. Visit the Adult Translational Research Unit (ATRU) seven times for consenting, screening, and checkups and tests
3. Keep a daily diary of their symptoms of persistent GERD

Start Date01 May 2025

Sponsor / Collaborator

Medical College of Wisconsin

NCT04383262

/ Not yet recruitingPhase 2IIT

A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir-Sodium Alginate Suspension for Laryngopharyngeal Reflux

Laryngopharyngeal reflux (LPR) causes chronic cough, throat clearing, hoarseness, and dysphagia and if left untreated can promote the development of laryngeal cancer. More than 20% of the United Stated population suffer from LPR, yet there is no effective medical therapy. Proton pump inhibitors (PPIs), which inhibit gastric acid production but do not prevent reflux events, continue to be prescribed for LPR despite their poor efficacy for this patient population, high cost ($26 billion/year), and associated risks. Pepsin, detected in the airway of these patients and now known to cause laryngeal inflammation and promote disease independent of gastric acid, is a key therapeutic target. We report preclinical studies of select HIV inhibitors that bind to and inhibit pepsin and thus hold promise for the treatment of LPR. In support, a very low incidence of LPR was found in patients taking these drugs compared to the general population. HIV inhibitors are ideal drugs to repurpose because they target a foreign virus. Thus, a repurposing approach can be used to safely perform proof of concept testing of the efficacy of a pepsin inhibitor for LPR. The Specific Aim of this project is to perform a 12-week randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of fosamprenavir-sodium alginate(FOS-SA) for LPR. FOS-SA will be used at the FDA approved, manufacturers recommended dose for HIV for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR and combined multi-channel intraluminal impedance - pH (MII-pH) confirmed laryngeal reflux events. Routine clinical outcome measures for LPR (Reflux Symptom Index, Reflux Finding Score, Voice Handicap Index) will be documented pre- and post-treatment with Oral Fosamprenavir-Sodium Alginate for LPR(n = 52) and placebo (n = 52). Additional research measures will include repeat administration of a newly created Daily Symptom Reflex Diary, as well as an intermittently distributed Patient Global Impression - Static & Change scales. Saliva will be collected pre-treatment for both pepsin protein analysis and kinetic activity assay to compare with clinical measures. There is currently no effective medical therapy for LPR and pepsin is the key therapeutic target. Identification of an FDA approved drug which inhibits pepsin allows for a clinical trial to determine efficacy using a faster and safer repurposing approach to address a significant gap.

Start Date01 Nov 2024

Sponsor / Collaborator

Medical College of Wisconsin

CTRI/2020/02/023247

/ CompletedNot Applicable

A single centre, site randomized, double-blind, comparative study to evaluate the impact of topical application of FOS and GOS on skin hydration, barrier function, and microbiome regulation in human adult subjects with dry, flaky skin, otherwise healthy.

Start Date14 Feb 2020

Sponsor / Collaborator

Tata Chemicals Ltd.

100 Clinical Results associated with Fosamprenavir calcium

100 Translational Medicine associated with Fosamprenavir calcium

100 Patents (Medical) associated with Fosamprenavir calcium

1,178

Literatures (Medical) associated with Fosamprenavir calcium

01 Dec 2025·Molecular Biology Reports

Development and utilization of a multiplex PCR assay for detecting three feline enteroviruses

Article

Author: Han, Xianjie ; Zhang, Ruihua ; Gao, Shansong ; Liu, Gang ; Yu, Yongle

BACKGROUNDFeline diarrhea is a common digestive tract disease in clinical practice, with watery feces as the main clinical manifestation. There are numerous pathogenic factors causing feline diarrhea, among which viral infections are prevalent, and feline panleukopenia virus (FPV) is the most common pathogen. In recent years, a variety of novel viruses have been detected in the intestines of cats with diarrhea. For example, feline kobuvirus (FKoV) and feline norovirus (FNoV) have been identified. These viruses may have a direct relationship with feline diarrhea or the connection has yet to be discovered. However, with the continuous emergence of these novel viruses and the frequent contact between pet cats and humans, it is prone to large-scale epidemics and outbreaks of viruses. Therefore, developing an accurate, rapid, and simple method to detect novel enteric viruses is of great significance for the early warning of emerging feline enteric viral infectious diseases.METHODS AND RESULTSA detailed comparison of the genome sequences of the three aforementioned feline enteroviruses was conducted. Subsequently, three pairs of specific primers were designed by selecting the conserved gene regions, and the single and multiplex PCR amplification reaction systems as well as reaction conditions were repeatedly optimized. The target fragment sizes detected by the multiplex PCR method were 650 bp for FPV, 500 bp for FKoV, and 340 bp for FNoV. Sensitivity tests demonstrated that the lower detection limit was one-tenth of that of single PCR. Meanwhile, the detection results for feline calicivirus (FCV), feline herpesvirus (FHV), and feline coronavirus (FCoV) were all negative. Testing of a total of 209 clinical samples from various regions in Shandong Province revealed that the detection rates of the three viruses were 13.4%, 4.8%, and 3.8%, respectively, and mixed infections were present.CONCLUSIONSIn this study, an epidemiological investigation of the three feline enteroviruses was performed, and a sensitive, specific, and reproducible multiplex PCR assay was developed, which can be utilized for the detection of clinical samples.

01 Jul 2025·Magnetic Resonance in Medicine

Machine learning‐based multi‐pool Voigt fitting of CEST, rNOE, and MTC in Z‐spectra

Article

Author: Prasuhn, Jannik ; Mohammed Ali, Sajad ; van Zijl, Peter C. M. ; Wirestam, Ronnie ; Knutsson, Linda ; Yadav, Nirbhay N.

AbstractPurposeFour‐pool Voigt (FPV) machine learning (ML)–based fitting for Z‐spectra was developed to reduce fitting times for clinical feasibility in terms of on‐scanner analysis and to promote larger cohort studies. The approach was compared to four‐pool Lorentzian (FPL)‐ML–based modeling to empirically verify the advantage of Voigt models for Z‐spectra.MethodsVoigt and Lorentzian models were fitted to human 3 T Z‐spectral data using least squares (LS) to generate training data for the corresponding ML versions. Gradient boosting decision trees were trained, resulting in one Voigt and one Lorentzian ML model. Modeling accuracy was tested, and the fitting times of the ML models and LS versions were evaluated. The goodness of fits of Voigt and Lorentzian ML models were compared.ResultsThe training time for each ML model (Voigt and Lorentzian) was less than 1 min, and the modeling accuracy compared to the corresponding LS versions was excellent, as indicated by a nonsignificant difference between the parameters obtained by LS and corresponding ML versions. The average fitting time was 20 μs/spectrum for both ML models compared to 0.27 and 0.82 s/spectrum for LS with FPL and FPV, respectively. The goodness of fits of FPV‐ML and FPL‐ML differed significantly (p < 0.005), with FPV‐ML showing an improvement for all tested data.ConclusionGradient boosting decision trees fitting of multi‐pool Z‐spectra significantly reduces fitting times compared to traditional LS approaches, allowing fast data processing while upholding fitting quality. Along with the short training times, this makes the method suitable for clinical settings and for large cohort research applications. The FPV‐ML approach provides a significant improvement of goodness of fit compared to FPL‐ML.

04 May 2025·Avian Pathology

The complexity of the interpretation of ELISA and RT-PCR results in the diagnosis of a reticuloendotheliosis virus infection: an extended case study

Article

Author: Dijkman, Remco ; Mamczur, Andrzej ; Wilczyński, Jaroslaw ; de Wit, Sjaak

Reticuloendotheliosis virus (REV) is a species of the genus Gammaretrovirus that can cause neoplasia, immunosuppression, and runting-stunting syndrome. To show the clinical relevance of REV is complicated, and requires the demonstration of the virus, REV antibodies, the presence of typical gross and microscopic lesions, and the exclusion of other oncogenic agents in the case of the presence of tumours. Under field conditions, the first tests to be used might be a commercially available REV antibody ELISA or an RT-PCR to detect the REV genome. In this short paper, we present the experiences with two commercially available ELISAs and RT-PCR that we have gained from a REV outbreak on a large multi-age layer farm and many follow-up tests on samples from control farms with and without a known history of REV and fowlpox virus (FPV). In the field, some of the FPV field strains contain large inserts of the REV genome that might interfere with REV testing. The results of the ELISAs on sera from REV- and FPV- unsuspected flocks suggested that the cut-offs of both ELISAs were somewhat low resulting in a lower specificity. However, cut-offs of 2000 and 3050 for the IDEXX and BioChek ELISAs, respectively, gave an agreement of 100%, suggesting that these cut-offs might be advisable to use. The use of the combination of RT-PCR for REV and PCR for FPV proved to be very useful in separating REV infections from FPV infections. The results of our extended field study can help to interpret REV testing results.

News (Medical) associated with Fosamprenavir calcium

29 Jan 2024

·www.biospace.com

Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections

Produced in the U.S., the generic anti-fungal drug is fully substitutable for Noxafil® LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi announced today it has introduced Posaconazole Injection, a generic substitute for Noxafil®, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules. This press release features multimedia. View the full release here: Fresenius Kabi Posaconazole Injection, a generic substitute for Noxafil® (Photo: Business Wire) Available in a 300 mg per 16.7 mL vial, Posaconazole Injection is used to treat invasive aspergillosis, a serious fungal infection, in adults and teenagers 13 years of age and older. It is also used to prevent invasive aspergillus and candida infections in patients who are severely immunocompromised, including adults and pediatric patients age 2 or older. “The introduction of Posaconazole Injection reflects Fresenius Kabi’s ongoing commitment to expanding our portfolio of affordable generic options for the treatment and/or prevention of life-threatening infections,” said John Ducker, president and CEO of Fresenius Kabi USA. Posaconazole Injection is produced at the company’s pharmaceutical production site in Grand Island, New York. Fresenius Kabi has invested nearly $1 billion to expand and update its U.S. pharmaceutical production and distribution network. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List. “We are doubling our U.S. manufacturing capacity to enhance the resilience of our supply chain, which helps assure fast, reliable service for our customers and the patients they serve,” said Lindsey Thomas, senior vice president of marketing of Fresenius Kabi USA. “Our investments will help patients gain access to the treatments they need – when and where they need them most.” Learn more about Fresenius Kabi’s commitment to strengthening its domestic supply chain at MoreInAmerica.com. About Fresenius Kabi Fresenius Kabi ( ) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at and follow us on LinkedIn. References *Noxafil® is a registered trademark of Merck Sharp & Dohme LLC. About Posaconazole Injection Posaconazole is an azole antifungal indicated as follows: Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: Posaconazole injection: adults and pediatric patients 2 years of age and older. IMPORTANT SAFETY INFORMATION Posaconazole is contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents. Coadministration of Posaconazole with the following drugs is contraindicated; Posaconazole increases concentrations and toxicities of: Sirolimus CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 Ergot alkaloids Venetoclax: in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp of phase Calcineurin-Inhibitor Toxicity: Posaconazole increases concentrations of cyclosporine or tacrolimus; reduce dose of cyclosporine and tacrolimus and monitor concentrations frequently. Arrhythmias and QTc Prolongation: Posaconazole has been shown to prolong the QTc interval and cause cases of TdP. Administer with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs known to prolong QTc interval and metabolized through CYP3A4. Electrolyte Disturbances: Monitor and correct, especially those involving potassium (K+), magnesium (Mg++), and calcium (Ca++), before and during Posaconazole therapy. Hepatic Toxicity: Elevations in liver tests may occur. Discontinuation should be considered in patients who develop abnormal liver tests or monitor liver tests during treatment. Renal Impairment: Posaconazole injection should be avoided in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min), unless an assessment of the benefit/risk to the patient justifies the use of Posaconazole injection. Concomitant Use with Midazolam: Posaconazole can prolong hypnotic/sedative effects. Monitor patients and benzodiazepine receptor antagonists should be available. Vincristine Toxicity: Concomitant administration of azole antifungals, including Posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions; reserve azole antifungals, including Posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options. Venetoclax Toxicity: Concomitant administration of Posaconazole with venetoclax may increase venetoclax toxicities, including the risk of tumor lysis syndrome, neutropenia, and serious infections; monitor for toxicity and reduce venetoclax dose. Adult Patients: Common adverse reactions in studies with Posaconazole in adults are diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia. Pediatric Patients: Common adverse reactions (incidence >20%) receiving 6 mg/kg Posaconazole injection in a study in pediatric patients are pyrexia, febrile neutropenia, vomiting, mucosal inflammation, pruritus, hypertension, hypokalemia, and stomatitis. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or . Drug Interactions: Interaction Drug Interaction Rifabutin, phenytoin, efavirenz Avoid coadministration unless the benefit outweighs the risks Other drugs metabolized by CYP3A4 Consider dosage adjustment and monitor for adverse effects and toxicity Digoxin Monitor digoxin plasma concentrations Fosamprenavir Monitor for breakthrough fungal infections Pregnancy: Based on animal data, may cause fetal harm. Pediatrics: Safety and effectiveness in patients younger than 2 years of age have not been established. Severe Renal Impairment: Monitor closely for breakthrough fungal infections. This Important Safety Information does not include all the information needed to use Posaconazole Injection safely and effectively. Please see the full prescribing information for Posaconazole Injection available at .

Drug Approval

21 Dec 2023

·synapse.patsnap.com

Understanding Proteases Inhibitors and Methods to Keep Abreast of Their Recent Developments

Proteases are enzymes that play a crucial role in the human body by breaking down proteins into smaller peptides or amino acids. These enzymes are involved in various physiological processes, including digestion, blood clotting, immune response, and cell signaling. Proteases help in the breakdown of dietary proteins into absorbable nutrients, aiding in digestion and nutrient absorption. They also regulate blood clotting by activating clotting factors. Additionally, proteases are involved in immune response by degrading foreign proteins and pathogens. Furthermore, these enzymes participate in cell signaling pathways, influencing various cellular processes such as growth, differentiation, and apoptosis. Overall, proteases are essential for maintaining proper protein homeostasis and ensuring the normal functioning of the human body. Viral proteases are a class of enzymes that hydrolyze the peptide chain structure of proteins and are essential enzymes for viral biosynthesis. Their function is to cleave and modify precursor proteins to obtain mature active proteins, thereby exerting normal physiological functions. Proteases play a crucial role in the life cycle of viruses, and proteases of different viruses have a certain degree of similarity. Therefore, viral proteases have become ideal targets in the development of broad-spectrum antiviral drugs. Most of the antiviral drugs approved by the Food and Drug Administration (FDA) are peptide analogs and macrocyclic compounds. They bind to the active site of the target protease, thereby exerting antiviral effects. Protease inhibitors against AIDS and Hepatitis C virus are the most innovative sources in the development of antiviral drugs, with at least half of antiviral drugs used to treat AIDS. FDA-approved protease inhibitors for AIDS include saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir, and combination preparations. The analysis of the target Protease in the pharmaceutical industry reveals a competitive landscape with companies at different stages of development. Shanghai Pharmaceutical (Group) Co., Ltd. is leading with an approved drug, while other companies are in Phase 1 or Preclinical stages. The approved indications cover a wide range of medical conditions, indicating the potential therapeutic applications of drugs targeting Protease. The drug types progressing rapidly include Enzyme, Small molecule drug, and Chemical drugs, with biosimilars contributing to intense competition. China, the United States, and European countries are actively developing drugs targeting Protease. The future development of the target Protease will depend on the success of ongoing research and development efforts, as well as the ability of companies to bring innovative drugs to market. How do they work?Protease inhibitors are a class of drugs that inhibit the activity of proteases, which are enzymes responsible for breaking down proteins. Proteases play a crucial role in various biological processes, including digestion, blood clotting, and immune response. By inhibiting proteases, protease inhibitors can interfere with these processes and have therapeutic effects. From a biomedical perspective, protease inhibitors are commonly used in the treatment of viral infections such as HIV/AIDS. HIV protease inhibitors specifically target the protease enzyme of the human immunodeficiency virus (HIV), preventing it from cleaving viral polyproteins into functional proteins. This inhibition disrupts the viral replication cycle and helps control the progression of HIV infection. Protease inhibitors can also be used in the treatment of other medical conditions, including hepatitis C, cancer, and certain autoimmune disorders. In cancer therapy, protease inhibitors can help prevent the growth and spread of tumors by blocking proteases involved in tumor invasion and angiogenesis. It is important to note that protease inhibitors can have side effects and may interact with other medications. Therefore, their use should be carefully monitored and prescribed by healthcare professionals. List of Protease InhibitorsThe currently marketed Protease inhibitors include: Chymotrypsin(Shanghai Pharmaceuticals Holding Co., Ltd.)ANG-003Bismuthyl EcabetChymotrypsinogen/trypsinogenCGT-1507EP-007FLT3 TriTACIgA proteases(IGAN Biosciences)MRX-18Aprotinin(Bayer Ag)For more information, please click on the image below. What are Protease inhibitors used for?Protease inhibitors are commonly used in the treatment of viral infections such as HIV/AIDS. For more information, please click on the image below to log in and search. How to obtain the latest development progress of Protease inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of Protease inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

28 Nov 2022

·www.biospace.com

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million

-- Company’s platform aims to create programmable, long-acting mRNA therapies that offer curative treatments for cancer and beyond -- -- Series A1 round led by new investor FPV Ventures -- BOSTON--(BUSINESS WIRE)-- Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million. New investor FPV led the round, with participation from Eli Lilly and Company, Potentum Partners, and existing investors Playground Global, and a further unannounced syndicate. This press release features multimedia. View the full release here: Strand Therapeutics co-founders Jake Becraft, Ph.D., CEO and Tasuku Kitada, Ph.D., President, Head of R&D. (Photo credit: Doug Levy) The funding will be used to advance Strand’s first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year. The funds will also be used to further develop its systemic delivery mechanism, which is designed to deliver tumor microenvironment-modifying mRNA to tumor sites and immune cells. To support these efforts, Strand will expand its multidisciplinary team across biology, bioengineering, bioinformatics, manufacturing, automation, and various G&A functions. Strand’s mission is to improve the efficacy, safety, ease of delivery and cost-effectiveness of treatments for deadly and chronic illnesses, through the use of long-acting programmable mRNA-based therapeutics that can deliver multi-functional treatments. mRNA therapeutics sense biomarkers found in cancer cells and express proteins only inside cancer cells. Strand is developing a pipeline of programmable, long-acting mRNA therapeutics that will be delivered in nanoparticles. The result is the ability to precisely control the location, timing, and expression level of mRNA within the patient, which is expected to have a better safety profile. “We raised this round at a step-up valuation from several of the most reputable global investors in the industry,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics. “The idea behind Strand and programmable mRNA in cancer, is to stimulate an immune response against the tumor using messenger RNA. With support from a world-class investor consortium, we are set to accelerate clinical development for our lead candidate in oncology with first-in-human data expected shortly following trial initiation. Our technology will enable mRNA to reach its full potential and expand beyond the scope of vaccines into a rigorous therapeutic modality.” “Strand is bringing the promise and potential of messenger RNA-based therapeutics beyond vaccines to treat some of the hardest diseases to target such as cancer,” said Pegah Ebrahimi, Co-Founder & Managing Partner of FPV. “mRNA is a future cornerstone of medicine, and Strand is on an ambitious path to push the industry beyond the challenges of traditional mRNA technologies with their precision. The convergence of biology and technology with next-generation programmable mRNA will fuel new opportunities for this ground-breaking technology to improve human lives, beginning with the millions of patients with cancer who desperately need new therapies with better efficacy and safety. We could not be more thrilled to back this remarkable team.” “The COVID-19 vaccines introduced the world to the astounding promise of mRNA therapeutics. While these vaccines literally saved the world, they represent “mRNA 1.0” which suffers from poor expression and nonspecific targeting of diseased tissues which have severely limited the scope of use,” said Jory Bell, General Partner at Playground. “Over a decade ago, scientists at MIT began developing a synthetic biology solution to enable truly programmable drugs with the ability to target diseased tissues while avoiding healthy tissues. Those scientists eventually founded Strand Therapeutics to realize the full potential of “mRNA 2.0” and we are thrilled to continue to support Strand in its mission to bring precision mRNA therapies to patients.” Strand genetically programs logic circuits that control the location, timing, and intensity of expression of therapeutic proteins within the patient’s body, to enable the precise and controlled delivery of multiple disease treatments in an RNA-modality agnostic manner. Such genetic programming enables Strand’s mRNA to sense and implement cell-type specific expression by sensing and classifying the unique microRNA expression signatures of cells. The company signed a partnership deal with BeiGene to develop and commercialize multi-functional mRNA treatments for solid tumors. About Strand Therapeutics Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics. Founded by leaders in mRNA-based synthetic biology at MIT, Strand is creating the first platform for programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of therapeutic activity. Strand’s mission is to develop improved treatment options for cancer and other life-threatening diseases. The company is headquartered in Boston, MA. For more information, visit . Follow us on Twitter @StrandTx. About FPV FPV is a new $450m fund focused on backing and serving mission-driven founders throughout their entire journey. Founded by industry veterans Wesley Chan (Founder of Google Analytics and Google Voice) and Pegah Ebrahimi (former COO and CIO at Morgan Stanley and COO of Cisco Collaboration), the firm has backed well-known, high-impact startups including Canva, Flexport, Guild Education, Xilis, and Manifold Bio.

VaccinemRNAsiRNA

100 Deals associated with Fosamprenavir calcium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fosamprenavir calcium	J05AE07	DB01319

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	Australia	ViiV Healthcare Ltd.	27 May 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpesviridae Infections	Discovery	United States	ViiV Healthcare Ltd.	01 Sep 2010
Mycoses	Discovery	Netherlands	GSK Plc	01 Jan 2009
HIV Infections	Discovery	United States	ViiV Healthcare Co.	20 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00802074 (CTgov)	Not Applicable	-	45	Fosamprenavir+Raltegravir (Group A)	lothzfnrxx(fqbsaaokds) = tgmkhnlbip vatsanuomf (akcbvcirof, tezdebmziv - idtmeeubjh) View more	-	29 Jan 2016
				Fosamprenavir+Raltegravir (Group B)	lothzfnrxx(fqbsaaokds) = afmqnzkjfd vatsanuomf (akcbvcirof, pimwivgmwj - nhfucjkelo) View more
NCT00764465 (CTgov)	Phase 2	-	45	Fosamprenavir+Maraviroc (Group A)	fvwpyrkyfi(jozildxhfm) = jybuybxile mqyqnlbvcq (aqqgptejvn, cdxilttcft - iymbraidbs) View more	-	29 Jan 2016
				Fosamprenavir+Maraviroc (Group B)	fvwpyrkyfi(jozildxhfm) = jarpsbfcrl mqyqnlbvcq (aqqgptejvn, pkegtwuebk - uuugnxbfzq) View more
NCT00614991 (CTgov)	Not Applicable	-	44	Fosamprenavir+Raltegravir (Group A)	kjeiizwqth(etouvtpuww) = ojipsbvnqn rmivckrexq (secvnpnfod, ywwpellthi - zuliulvyxy) View more	-	29 Jan 2016
				Fosamprenavir+Raltegravir (Group B)	kjeiizwqth(etouvtpuww) = gtdhtixgkw rmivckrexq (secvnpnfod, klpkgyapht - umdkwfxldq) View more
NCT00318474 (CTgov)	Phase 3	Glomerulonephritis, IGA	184	ACEi+FOS+Mycophenolate Mofetil (MMF)	cucejfyhdy(iiihhrucue) = crabypxmwn yykceatour (ofqgpihaqn, zgdngzyciw - hzwrgfpsvu) View more	-	01 Oct 2014
NCT00242216 (CTgov)	Phase 4	HIV Infections	76	Atazanavir (Atazanavir)	utjtlvthoc(spcngcoxln) = iepdjvvmiz pcwmmquxbr (kkmkxoeatt, askwwckbkk - pmerfojlmp) View more	-	17 Oct 2013
				Fosamprenavir (Fosamprenavir)	utjtlvthoc(spcngcoxln) = ptlndjvlxq pcwmmquxbr (kkmkxoeatt, uowqnlyolc - yecdquibtn) View more
NCT00089583 (CTgov)	Phase 2	HIV Infections	110	FPV (FPV Treatment Group)	veogsuwtta(czhtxncjxr) = zilocrqzqz efueglctos (rstajhaias, wngkwuanqr - bkcbkjolev) View more	-	21 Jun 2012
				FPV+RTV (FPV/RTV Treatment Group)	veogsuwtta(czhtxncjxr) = nxkhjpxorp efueglctos (rstajhaias, bfpvfjzodw - kyzwtbxsaj) View more
IAS2011	Not Applicable	Hypertriglyceridemia	36	Switch to boosted fosamprenavir once-daily	wvhjyrgmug(walchtwqxt) = lacqdwrenu kfnnlpspdf (xxjicssfzh )	-	01 Jan 2011
				Lovaza 4g QD	wvhjyrgmug(walchtwqxt) = xnsayagidm kfnnlpspdf (xxjicssfzh )
IAS2011	Not Applicable	HIV Infections	151	Fosamprenavir with low-dose ritonavir	(rthblpijnu) = bogowvytet mfhiaghfhv (mzuyoicxok )	-	01 Jan 2011
ESS100290 (IAS2008)	Not Applicable	HIV Infections	-	FPV-switch	ilkqieazgt(uktdzzlrww) = afrlpvsjcb umzkaqufmr (ndvmmfrpeh ) View more	-	01 Jan 2008
				BL-PI	ilkqieazgt(uktdzzlrww) = xxwmyjlrdl umzkaqufmr (ndvmmfrpeh ) View more
COL100758 (IAS2007)	Not Applicable	-	115	FPV/r 1400mg/100mg	snjtslavfn(ryhrtakdoh) = sbhljynesi svyrngiurd (mqnuaebvtf ) View more	-	01 Jan 2007
				FPV/r 1400mg/200mg	snjtslavfn(ryhrtakdoh) = cwtyumadtf svyrngiurd (mqnuaebvtf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis